CELL SEARCH SYSTEM -CELL BANK- (RIKEN BRC) [RCB0805 : Ba/F3]

4829 Daley GQ1, Baltimore D. Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein. Proc Natl Acad Sci U S A 1988 85(23):9312-6 PubMed ID: 3143116 DOI: 10.1073/pnas.85.23.9312

4828 Palacios R, Steinmetz M. Il-3-dependent mouse clones that express B-220 surface antigen, contain Ig genes in germ-line configuration, and generate B lymphocytes in vivo. Cell 1985 41(3):727-34 PubMed ID: 3924409 DOI: 10.1016/s0092-8674(85)80053-2

4827 Palacios R, Henson G, Steinmetz M, McKearn JP. Interleukin-3 supports growth of mouse pre-B-cell clones in vitro. Nature 1984 309(5964):126-31 PubMed ID: 6201749 DOI: 10.1038/309126a0

Top

User's Publication

19799 Hata T, Uematsu Y, Sugita A, Adachi H, Kato S, Hirate M, Ishikura KI, Kaku A, Ohara H, Kojima N, Takahashi T, Kurokawa T. A Potent Neutralizing Monoclonal Antibody to Human Growth Hormone Suppresses Insulin-Like Growth Factor-1 in female Rats Endocrinology 2024 Mar 19:bqae033 PubMed ID: 38500360 DOI: 10.1210/endocr/bqae033

21641 Umene K, Kawahara M. Synthetic receptor scaffolds significantly affect the efficiency of cell fate signals. Sci Rep 2024 14(1):5801 PubMed ID: 38461201 DOI: 10.1038/s41598-024-56612-2

21701 Watanabe H, Inoue Y, Karayama M, Yazawa S, Mochizuka Y, Yasui H, Hozumi H, Suzuki Y, Furuhashi K, Enomoto N, Fujisawa T, Shinmura K, Inui N, Suda T. Characterization of BRAFThr599dup Mutation as a Targetable Driver Mutation Identified in Lung Adenocarcinoma by Comprehensive Genomic Profiling. JCO Precis Oncol 2024 8:e2300538 PubMed ID: 38662982 DOI: 10.1200/PO.23.00538

21899 Takeda K, Ohta S, Nagao M, Kobayashi E, Tago K, Funakoshi-Tago M. FL118 Is a Potent Therapeutic Agent against Chronic Myeloid Leukemia Resistant to BCR-ABL Inhibitors through Targeting RNA Helicase DDX5 Int J Mol Sci 2024 25(7):3693 PubMed ID: 38612503 DOI: 10.3390/ijms25073693

21981 Lin JJ, Horan JC, Tangpeerachaikul A, Swalduz A, Valdivia A, Johnson ML, Besse B, Camidge DR, Fujino T, Yoda S, Nguyen-Phuong L, Mizuta H, Bigot L, Nobre C, Lee JB, Yu MR, Mente S, Sun Y, Kohl NE, Porter JR, Shair MD, Zhu VW, Felip E, Cho BC, Friboulet L, Hata AN, Pelish HE, Drilon A. NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations. Cancer Discov 2024 OF1-OF20 PubMed ID: 39269178 DOI: 10.1158/2159-8290.CD-24-0231

19719 Garbers C, Rose-John S. Dissecting Interleukin-6 Classic and Trans-signaling in Inflammation and Cancer Methods Mol Biol 2023 2691:207-224 PubMed ID: 37355548 DOI: 10.1007/978-1-0716-3331-1_16

19751 Koga T, Soh J, Hamada A, Miyano Y, Fujino T, Obata K, Ohara S, Nishino M, Chiba M, Shimoji M, Takemoto T, Suda K, Sakai K, Sato H, Mitsudomi T. Clinical Relevance of Patient-Derived Organoid of Surgically Resected Lung Cancer as an In Vitro Model for Biomarker and Drug Testing JTO Clin Res Rep 2023 4(9):100554 PubMed ID: 37681218 DOI: 10.1016/j.jtocrr.2023.100554

19977 Ochi N, Takeyama M, Miyake N, Fuchigami M, Yamane H, Fukazawa T, Nagasaki Y, Kawahara T, Nakanishi H, Takigawa N. The complexity of EGFR exon 19 deletion and L858R mutant cells as assessed by proteomics, transcriptomics, and metabolomics Exp Cell Res 2023 424(1):113503 PubMed ID: 36731710 DOI: 10.1016/j.yexcr.2023.113503

21235 Lim SM, Fujino T, Kim C, Lee G, Lee YH, Kim DW, Ahn JS, Mitsudomi T, Jin T, Lee SY. BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer. Clin Cancer Res 2023 PubMed ID: 37249619 DOI: 10.1158/1078-0432.CCR-22-3901

21407 Umene K, Nagamune T, Kawahara M. Phenotypic screening of signaling motifs that efficiently induce cell proliferation. Sci Rep 2023 13(1):15639 PubMed ID: 37730760 DOI: 10.1038/s41598-023-42378-6

21617 Okura Y, Ikawa-Teranishi Y, Mizoroki A, Takahashi N, Tsushima T, Irie M, Harfuddin Z, Miura-Okuda M, Ito S, Nakamura G, Takesue H, Ozono Y, Nishihara M, Yamada K, Gan SW, Hayasaka A, Ishii S, Wakabayashi T, Muraoka M, Nagaya N, Hino H, Nemoto T, Kuramochi T, Torizawa T, Shimada H, Kitazawa T, Okazaki M, Nezu J, Sollid LM, Igawa T. Characterizations of a neutralizing antibody broadly reactive to multiple gluten peptide:HLA-DQ2.5 complexes in the context of celiac disease. Nat Commun 2023 14(1):8502 PubMed ID: 38135691 DOI: 10.1038/s41467-023-44083-4

17495 Sakashita T, Yanagitani N, Koike S, Low SK, Takagi S, Baba S, Takeuchi K, Nishio M, Fujita N, Katayama R. Fibroblast growth factor receptor 3 overexpression mediates ALK inhibitor resistance in ALK-rearranged non-small cell lung cancer Cancer Sci 2022 113(11):3888-3900 PubMed ID: 35950895 DOI: 10.1111/cas.15529

17578 Mitani Y, Ohashi S, Kikuchi O, Nakai Y, Ida T, Mizumoto A, Yamamoto Y, Saito T, Kataoka S, Matsubara J, Yamada A, Kanai M, Matsumoto S, Sakai H, Yoshikawa K, Nakamura E, Muto M. HER2 G776S mutation promotes oncogenic potential in colorectal cancer cells when accompanied by loss of APC function Sci Rep 2022 12(1):9213 PubMed ID: 35654814 DOI: 10.1038/s41598-022-13189-y

17697 Furugaki K, Harada N, Yoshimura Y. Sensitivity of eight types of ALK fusion variant to alectinib in ALK-transformed cells Anticancer Drugs 2022 33(2):124-131 PubMed ID: 34520436 DOI: 10.1097/CAD.0000000000001249

20414 Miyauchi M, Sasaki K, Kagoya Y, Taoka K, Masamoto Y, Yamazaki S, Arai S, Mizuno H, Kurokawa M. CAMK2G is identified as a novel therapeutic target for myelofibrosis. Blood Adv 2022 PubMed ID: 34521112 DOI: 10.1182/bloodadvances.2020003303

16227 Kazuya Sumi, Kenji Tago, Yosuke Nakazawa, Kyoko Takahashi, Tomoyuki Ohe, Tadahiko Mashino, Megumi Funakoshi-Tago Novel Mechanism by a Bis-Pyridinium Fullerene Derivative to Induce Apoptosis by Enhancing the MEK-ERK Pathway in a Reactive Oxygen Species-Independent Manner in BCR-ABL-Positive Chronic Myeloid Leukemia-Derived K562 Cells Int J Mol Sci 2022 23(2):749 PubMed ID: 35054935 DOI: 10.3390/ijms23020749

16427 Koga T, Suda K, Mitsudomi T. Utility of the Ba/F3 cell system for exploring on-target mechanisms of resistance to targeted therapies for lung cancer Cancer Sci 2022 113(3):815-827 PubMed ID: 34997674 DOI: 10.1111/cas.15263

20617 Miura T, Kawano M, Takahashi K, Yuasa N, Habu M, Kimura F, Imamura T, Nakayama F. High-Sulfated Hyaluronic Acid Ameliorates Radiation-Induced Intestinal Damage Without Blood Anticoagulation. Adv Radiat Oncol 2022 7(3):100900 PubMed ID: 35295873 DOI: 10.1016/j.adro.2022.100900

20731 Shiba-Ishii A, Johnson TW, Dagogo-Jack I, Mino-Kenudson M, Johnson TR, Wei P, Weinrich SL, McTigue MA, Walcott MA, Nguyen-Phuong L, Dionne K, Acker A, Kiedrowski LA, Do A, Peterson JL, Barth JL, Yeap BY, Gainor JF, Lin JJ, Yoda S, Hata AN. Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer. Nat Cancer 2022 PubMed ID: 35726063 DOI: 10.1038/s43018-022-00399-6

16770 Fujino T, Suda K, Koga T, Hamada A, Ohara S, Chiba M, Shimoji M, Takemoto T, Soh J, Mitsudomi T. Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation J Hematol Oncol 2022 15(1):79 PubMed ID: 35690785 DOI: 10.1186/s13045-022-01299-z

20905 Kwak C, Park C, Ko M, Im CY, Moon H, Park YH, Kim SY, Lee S, Kang MG, Kwon HJ, Hong E, Seo JK, Rhee HW. Identification of proteomic landscape of drug-binding proteins in live cells by proximity-dependent target ID. Cell Chem Biol 2022 PubMed ID: 36272407 DOI: 10.1016/j.chembiol.2022.10.001

20910 Kimura Y, Kashima D, Kawahara M. A growth-based platform for detecting domain-peptide interactions in the cytoplasm of mammalian cells. Sci Rep 2022 12(1):18028 PubMed ID: 36302843 DOI: 10.1038/s41598-022-22770-4

20920 Okuda H, Miyamoto R, Takahashi S, Kawamura T, Ichikawa J, Harada I, Tamura T, Yokoyama A. RNA-binding proteins of KHDRBS and IGF2BP families control the oncogenic activity of MLL-AF4. Nat Commun 2022 13(1):6688 PubMed ID: 36335100 DOI: 10.1038/s41467-022-34558-1

20930 Mendivil-Perez M, Jimenez-Del-Rio M, Velez-Pardo C. TPEN/TPGS (T2) combo dramatically reduces Philadelphia chromosome-positive pro-lymphoblastic B leukemia in BALB/c mice. Med Oncol 2022 40(1):15 PubMed ID: 36352172 DOI: 10.1007/s12032-022-01873-y

12148 David Koschut, Debleena Ray, Zhenhua Li, Emanuela Giarin, Jürgen Groet, , Ivan Alić, Shirley Kow-Yin Kham, , Wee Joo Chng, Hany Ariffin, , David M. Weinstock, , Allen Eng-Juh Yeoh, , Giuseppe Basso, , Dean Nižetić RAS-protein activation but not mutation status is an outcome predictor and unifying therapeutic target for high-risk acute lymphoblastic leukemia Oncogene 2021 40(4):746-762 PubMed ID: 33247204 DOI: 10.1038/s41388-020-01567-7

20107 Jia W, Kong L, Kidoya H, Naito H, Muramatsu F, Hayashi Y, Hsieh HY, Yamakawa D, Hsu DK, Liu FT, Takakura N. Indispensable role of Galectin-3 in promoting quiescence of hematopoietic stem cells. Nat Commun 2021 12(1):2118 PubMed ID: 33837181 DOI: 10.1038/s41467-021-22346-2

20184 Kashima D, Kawahara M. Evolution of KIPPIS as a versatile platform for evaluating intracellularly functional peptide aptamers. Sci Rep 2021 11(1):11758 PubMed ID: 34083659 DOI: 10.1038/s41598-021-91287-z

20317 Kongkrongtong T, Zhang R, Kawahara M. Rational design of heterodimeric receptors capable of activating target signaling molecules. Sci Rep 2021 11(1):16809 PubMed ID: 34413422 DOI: 10.1038/s41598-021-96396-3

15885 Ryo Nagai, Takeru Ebihara, Kohei Kakino, Akitsu Masuda, Jian Xu, Kosuke Minamihata, Noriho Kamiya, Tatphon Kongkrongtong, Masahiro Kawahara, Hiroaki Mon, Tsuguru Fujii, Takahiro Kusakabe, Jae Man Lee Production of an active Mus musculus IL-3 using updated silkworm-based baculovirus expression vector system Journal of Asia-Pacific Entomology 2021 24:544-549 DOI: 10.1016/j.aspen.2021.04.011

16098 Tanaka N, Lin JJ, Li C, Ryan MB, Zhang J, Kiedrowski LA, Michel AG, Syed MU, Fella KA, Sakhi M, Baiev I, Juric D, Gainor JF, Klempner SJ, Lennerz JK, Siravegna G, Bar-Peled L, Hata AN, Heist RS, Corcoran RB. Clinical Acquired Resistance to KRAS G12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS-MAPK Reactivation Cancer Discov 2021 11(8):1913-1922 PubMed ID: 33824136 DOI: 10.1158/2159-8290.CD-21-0365

16117 Koga T, Suda K, Fujino T, Ohara S, Hamada A, Nishino M, Chiba M, Shimoji M, Takemoto T, Arita T, Gmachl M, Hofmann MH, Soh J, Mitsudomi T KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments J Thorac Oncol 2021 16(8):1321-1332 PubMed ID: 33971321 DOI: 10.1016/j.jtho.2021.04.015

16769 Koya Y, Nara H, Yagi S, Ueno C, Kamohara M. An engineered tetra-valent antibody fully activates the Tie2 receptor with comparable potency to its natural ligand angiopoietin-1 Sci Rep 2021 11(1):14021 PubMed ID: 34234265 DOI: 10.1038/s41598-021-93660-4

16774 Koga T, Suda K, Nishino M, Fujino T, Ohara S, Hamada A, Soh J, Tirunagaru V, Vellanki A, Doebele RC, Mitsudomi T. Activity and mechanism of acquired resistance to tarloxotinib in HER2 mutant lung cancer: an in vitro study Transl Lung Cancer Res 2021 10(8):3659-3670 PubMed ID: 34584864 DOI: 10.21037/tlcr-21-216

11561 Yamada R, Fukumoto R, Noyama C, Fujisawa A, Oka S, Imamura T. An epidermis-permeable dipeptide is a potential cosmetic ingredient with partial agonist/antagonist activity toward fibroblast growth factor receptors. J Cosmet Dermatol 2020 19(2):477-484 PubMed ID: 31099492 DOI: 10.1111/jocd.12997

12115 Hirai N, Sasaki T, Okumura S, Minami Y, Chiba S, Ohsaki Y. Monomerization of ALK Fusion Proteins as a Therapeutic Strategy in ALK-Rearranged Non-small Cell Lung Cancers. Front Oncol 2020 PubMed ID: 32300555 DOI: 10.3389/fonc.2020.00419

13011 Tanaka H, Negoro K, Koike T, Tsukamoto I, Yokoyama K, Maeda J, Inagaki Y, Shimoshige Y, Ino K, Ishizu K, Takahashi T. Discovery and structure-activity relationships study of positive allosteric modulators of the M₃ muscarinic acetylcholine receptor. Bioorg Med Chem 2020 PubMed ID: 32386953 DOI: 10.1016/j.bmc.2020.115531

13901 Yamahira S, Heike Y. Facile Fabrication of Thin-Bottom Round-Well Plates Using the Deformation of PDMS Molds and Their Application for Single-Cell PCR Micromachines (Basel) 2020 11(8):748 PubMed ID: 32751967 DOI: 10.3390/mi11080748

11428 Kang JH, Miettinen TP, Chen L, Olcum S, Katsikis G, Doyle PS, Manalis SR. Noninvasive monitoring of single-cell mechanics by acoustic scattering. Nat. Methods 2019 PubMed ID: 30742041 DOI: 10.1038/s41592-019-0326-x

4862 Yonesaka K, Kobayashi Y, Hayashi H1, Chiba Y, Mitsudomi T, Nakagawa K. Dual blockade of EGFR tyrosine kinase using osimertinib and afatinib eradicates EGFR‑mutant Ba/F3 cells. Oncol Rep 2019 1(2):1059-1066 PubMed ID: 30483795 DOI: 10.3892/or.2018.6881

4865 Eguchi A, Nakakido M, Nagatoishi S, Kuroda D, Tsumoto K, Nagamune T, Kawahara M. An epitope-directed antibody affinity maturation system utilizing mammalian cell survival as readout. Biotechnol Bioeng 2019 116(7):1742-1751 PubMed ID: 30883677 DOI: 10.1002/bit.26965

4870 Udagawa H#1, Hasako S#2, Ohashi A, Fujioka R, Hakozaki Y, Shibuya M, Abe N, Komori T, Haruma T, Terasaka M, Fujita R, Hashimoto A, Funabashi K, Yasuda H, Miyadera K, Goto K, Costa DB, Kobayashi S. TAS6417/CLN-081 Is a Pan-Mutation-Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant EGFR Mutations. Mol Cancer Res 2019 17(11):2233-2243 PubMed ID: 31467113 DOI: 10.1158/1541-7786.MCR-19-0419

4872 Tanaka H, Sakagami H, Kaneko N, Konagai S, Yamamoto H, Matsuya T, Yuri M, Yamanaka Y, Mori M, Takeuchi M, Koshio H, Hirano M, Kuromitsu S. Mutant-Selective Irreversible EGFR Inhibitor, Naquotinib, Inhibits Tumor Growth in NSCLC Models with EGFR-Activating Mutations, T790M Mutation, and AXL Overexpression. Mol Cancer Ther 2019 18(8):1366-1373 PubMed ID: 31092564 DOI: 10.1158/1535-7163.MCT-18-0976

4875 Yuki Uchiharaa, Tomoyuk iOhe, Tadahiko Mashino, Takayuki Kidokoro, Kenji Tago, Hiroomi Tamura, Megumi Funakoshi-Tago N-Acetyl cysteine prevents activities of STAT3 inhibitors, Stattic and BP-1-102 independently of its antioxidant properties Pharmacol Rep 2019 71(6):1067-1078 PubMed ID: 31627175 DOI: 10.1016/j.pharep.2019.05.021

11622 Fujino T, Kobayashi Y, Suda K, Koga T, Nishino M, Ohara S, Chiba M, Shimoji M, Tomizawa K, Takemoto T, Mitsudomi T. Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In Vitro. J Thorac Oncol 2019 14(10):1753-1765 PubMed ID: 31279006 DOI: 10.1016/j.jtho.2019.06.023

6896 Kim HJ, Kim HJ, Kim MK, Bae MK, Sung HY, Ahn JH, Kim YH, Kim SC, Ju W. SPSB1 enhances ovarian cancer cell survival by destabilizing p21. Biochem Biophys Res Commun 2019 510(3):364-369 PubMed ID: 30712944 DOI: 10.1016/j.bbrc.2019.01.088

12393 Futami T, Kawase T, Mori K, Asaumi M, Kihara R, Shindoh N, Kuromitsu S. Identification of a novel oncogenic mutation of FGFR4 in gastric cancer Sci Rep 2019 9(1):14627 PubMed ID: 31601997 DOI: 10.1038/s41598-019-51217-6

12394 Kawase T, Nakazawa T, Eguchi T, Tsuzuki H, Ueno Y, Amano Y, Suzuki T, Mori M, Yoshida T. Effect of Fms-like tyrosine kinase 3 (FLT3) ligand (FL) on antitumor activity of gilteritinib, a FLT3 inhibitor, in mice xenografted with FL-overexpressing cells Oncotarget 2019 10(58):6111-6123 PubMed ID: 31692922 DOI: 10.18632/oncotarget.27222

10032 Oyama S, Kitamura H, Kuramochi T, Higuchi Y, Matsushita H, Suzuki T, Goto M, Adachi H, Kasutani K, Sakamoto A, Iwayanagi Y, Kaneko A, Nanami M, Fujii E, Esaki K, Takashima Y, Shimaoka S, Hattori K, Kawabe Y. Cynomolgus monkey model of interleukin-31-induced scratching depicts blockade of human interleukin-31 receptor A by a humanized monoclonal antibody. Exp. Dermatol. 2018 27:14-21 PubMed ID: 27714851 DOI: 10.1111/exd.13236

4160 Koga T, Kobayashi Y, Tomizawa K, Suda K, Kosaka T, Sesumi Y, Fujino T, Nishino M, Ohara S, Chiba M, Shimoji M, Takemoto T, Suzuki M, Jänne PA, Mitsudomi T. Activity of a novel HER2 inhibitor, poziotinib, for HER2 exon 20 mutations in lung cancer and mechanism of acquired resistance: An in vitro study. Lung Cancer 2018 PubMed ID: 30527195 DOI: 10.1016/j.lungcan.2018.10.019

4161 Kobayashi Y, Fujino T, Nishino M, Koga T, Chiba M, Sesumi Y, Ohara S, Shimoji M, Tomizawa K, Takemoto T, Mitsudomi T. EGFR T790M and C797S Mutations as Mechanisms of Acquired Resistance to Dacomitinib. J Thorac Oncol 2018 PubMed ID: 29410323 DOI: 10.1016/j.jtho.2018.01.009

4162 Uchihara Y, Tago K, Taguchi H, Narukawa Y, Kiuchi F, Tamura H, Funakoshi-Tago M. Taxodione induces apoptosis in BCR-ABL-positive cells through ROS generation. Biochem. Pharmacol. 2018 PubMed ID: 29859988 DOI: 10.1016/j.bcp.2018.05.018

4163 Funahashi SI, Kawai S, Fujii E, Taniguchi K, Nakano K, Ishikawa S, Aburatani H, Suzuki M. Generation of an anti-desmoglein 3 antibody without pathogenic activity of pemphigus vulgaris for therapeutic application to squamous cell carcinoma. J. Biochem. 2018 PubMed ID: 30239818 DOI: 10.1093/jb/mvy074

4164 Yoshida H, Yamada H, Nogami W, Dohi K, Kurino-Yamada T, Sugiyama K, Takahashi K, Gahara Y, Kitaura M, Hasegawa M, Oshima I, Kuwabara K. Development of a new knock-in mouse model and evaluation of pharmacological activities of lusutrombopag, a novel, nonpeptidyl small-molecule agonist of the human thrombopoietin receptor c-Mpl. Exp. Hematol. 2018 PubMed ID: 29274361 DOI: 10.1016/j.exphem.2017.12.005

4269 Hirao T, Yamaguchi M, Kikuya M, Chibana H, Ito K, Aoki S. Altered intracellular signaling by imatinib increases the anti-cancer effects of tyrosine kinase inhibitors in chronic myelogenous leukemia cells. Cancer Sci. 2018 PubMed ID: 29121435 DOI: 10.1111/cas.13442

4471 Katayama K, Noguchi K, Sugimoto Y. Heat shock protein 90 inhibitors overcome the resistance to Fms-like tyrosine kinase 3 inhibitors in acute myeloid leukemia. Oncotarget 2018 9(76):34240-34258 PubMed ID: 30344940 DOI: 10.18632/oncotarget.26045

15838 Hasako S, Terasaka M, Abe N, Uno T, Ohsawa H, Hashimoto A, Fujita R, Tanaka K, Okayama T, Wadhwa R, Miyadera K, Aoyagi Y, Yonekura K, Matsuo K. TAS6417, A Novel EGFR Inhibitor Targeting Exon 20 Insertion Mutations Mol Cancer Ther 2018 17(8):1648-1658 PubMed ID: 29748209 DOI: 10.1158/1535-7163.MCT-17-1206

10205 Nguyen TD, Takasuka H, Kaku Y, Inoue S, Nagamune T, Kawahara M. Engineering a growth sensor to select intracellular antibodies in the cytosol of mammalian cells. J. Biosci. Bioeng. 2017 124:125-132 PubMed ID: 28319021 DOI: 10.1016/j.jbiosc.2017.02.017

10264 Nagata N, Iwanari H, Kumagai H, Kusano-Arai O, Ikeda Y, Aritake K, Hamakubo T, Urade Y. Generation and characterization of an antagonistic monoclonal antibody against an extracellular domain of mouse DP2 (CRTH2/GPR44) receptors for prostaglandin D2. PLoS ONE 2017 12:e0175452 PubMed ID: 28394950 DOI: 10.1371/journal.pone.0175452

10272 Chiba M, Togashi Y, Bannno E, Kobayashi Y, Nakamura Y, Hayashi H, Terashima M, De Velasco MA, Sakai K, Fujita Y, Mitsudomi T, Nishio K. Efficacy of irreversible EGFR-TKIs for the uncommon secondary resistant EGFR mutations L747S, D761Y, and T854A. BMC Cancer 2017 17:281 PubMed ID: 28424065 DOI: 10.1186/s12885-017-3263-z

4570 Funahashi SI, Suzuki Y, Nakano K, Kawai S, Suzuki M. Generation and characterization of monoclonal antibodies against human LGR6. J Biochem 2017 161(4):361-368 PubMed ID: 28013222 DOI: 10.1093/jb/mvw077

4842 Kim SY, Ahn T, Bang H, Ham JS, Kim J, Kim ST, Jang J, Shim M, Kang SY, Park SH, Min BH, Lee H, Kang WK, Kim KM, Park W, Lee J. Acquired resistance to LY2874455 in FGFR2-amplified gastric cancer through an emergence of novel FGFR2-ACSL5 fusion. Oncotarget 2017 8(9):15014-15022 PubMed ID: 28122360 DOI: 10.18632/oncotarget.14788

4859 Cho J, Kim SY, Kim YJ, Sim MH, Kim ST, Kim NKD, Kim K, Park W, Kim JH, Jang KT, Lee J. Emergence of CTNNB1 mutation at acquired resistance to KIT inhibitor in metastatic melanoma. Clin Transl Oncol 2017 19(10):1247-1252 PubMed ID: 28421416 DOI: 10.1007/s12094-017-1662-x

4873 Watanabe M, Nakano K, Kadin ME, Higashihara M, Watanabe T, Horie R. CD30 Induces Heat Shock Protein 90 and Signal Integration in Classic Hodgkin Lymphoma Cells. Am J Pathol 2017 187(1):163-175 PubMed ID: 27870927 DOI: 10.1016/j.ajpath.2016.09.007

4878 Uchihara Y, Ueda F, Tago K, Nakazawa Y, Ohe T, Mashino T, Yokota S, Kasahara T, Tamura H, Funakoshi-Tago M. Alpha-tocopherol attenuates the anti-tumor activity of crizotinib against cells transformed by NPM-ALK. PLoS One 2017 12(8):e0183003 PubMed ID: 28806414 DOI: 10.1371/journal.pone.0183003

14040 Aihara A, Koike T, Abe N, Nakamura S, Sawaguchi A, Nakamura T, Sugimoto N, Nakauchi H, Nishino T, Eto K. Novel TPO receptor agonist TA-316 contributes to platelet biogenesis from human iPS cells Blood Adv 2017 1(7):468-476 PubMed ID: 29296963 DOI: 10.1182/bloodadvances.2016000844

10912 Izuta S, Yamaguchi S, Misawa R, Yamahira S, Tan M, Kawahara M, Suzuki T, Takagi T, Sato K, Nakamura M, Nagamune T, Okamoto A. Microfluidic preparation of anchored cell membrane sheets for in vitro analyses and manipulation of the cytoplasmic face Sci Rep 2017 7(1):14962 PubMed ID: 29097751 DOI: 10.1038/s41598-017-14737-7

14690 Ogura H, Nagatake-Kobayashi Y, Adachi J, Tomonaga T, Fujita N, Katayama R. TKI-addicted ROS1-rearranged cells are destined to survival or death by the intensity of ROS1 kinase activity Sci Rep 2017 7(1):5519 PubMed ID: 28717217 DOI: 10.1038/s41598-017-05736-9

17940 Gainor JF, Dardaei L, Yoda S, Friboulet L, Leshchiner I, Katayama R, Dagogo-Jack I, Gadgeel S, Schultz K, Singh M, Chin E, Parks M, Lee D, DiCecca RH, Lockerman E, Huynh T, Logan J, Ritterhouse LL, Le LP, Muniappan A, Digumarthy S, Channick C, Keyes C, Getz G, Dias-Santagata D, Heist RS, Lennerz J, Sequist LV, Benes CH, Iafrate AJ, Mino-Kenudson M, Engelman JA, Shaw AT. Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer Cancer Discov 2016 6(10):1118-1133 PubMed ID: 27432227 DOI: 10.1158/2159-8290.CD-16-0596

4852 Miura T, Nagamune T, Kawahara M. Ligand-inducible dimeric antibody for selecting antibodies against a membrane protein based on mammalian cell proliferation. Biotechnol Bioeng 2016 113(5):1113-23 PubMed ID: 26479395 DOI: 10.1002/bit.25858

4860 Ishibashi T, Yaguchi A, Terada K, Ueno-Yokohata H, Tomita O, Iijima K, Kobayashi K, Okita H, Fujimura J, Ohki K, Shimizu T, Kiyokawa N. Ph-like ALL-related novel fusion kinase ATF7IP-PDGFRB exhibits high sensitivity to tyrosine kinase inhibitors in murine cells. Exp Hematol 2016 44(3):177-88.e5 PubMed ID: 26703895 DOI: 10.1016/j.exphem.2015.11.009

14140 Stevens MM, Maire CL, Chou N, Murakami MA, Knoff DS, Kikuchi Y, Kimmerling RJ, Liu H, Haidar S, Calistri NL, Cermak N, Olcum S, Cordero NA, Idbaih A, Wen PY, Weinstock DM, Ligon KL, Manalis SR. Drug sensitivity of single cancer cells is predicted by changes in mass accumulation rate Nat Biotechnol 2016 34(11):1161-1167 PubMed ID: 27723727 DOI: 10.1038/nbt.3697

4843 Trung LQ, Espinoza JL, An DT, Viet NH1, Shimoda K, Nakao S. Resveratrol selectively induces apoptosis in malignant cells with the JAK2V617F mutation by inhibiting the JAK2 pathway. Mol Nutr Food Res 2015 59(11):2143-54 PubMed ID: 26375873 DOI: 10.1002/mnfr.201500166

4849 Fujita T, Yuno M, Okuzaki D, Ohki R, Fujii H. Identification of non-coding RNAs associated with telomeres using a combination of enChIP and RNA sequencing. PLoS One 2015 10(4):e0123387 PubMed ID: 25874893 DOI: 10.1371/journal.pone.0123387

14974 Ota K, Azuma K, Kawahara A, Hattori S, Iwama E, Tanizaki J, Harada T, Matsumoto K, Takayama K, Takamori S, Kage M, Hoshino T, Nakanishi Y, Okamoto I. Induction of PD-L1 Expression by the EML4-ALK Oncoprotein and Downstream Signaling Pathways in Non-Small Cell Lung Cancer Clin Cancer Res 2015 21(17):4014-21 PubMed ID: 26019170 DOI: 10.1158/1078-0432.CCR-15-0016

15120 Kobayashi Y, Togashi Y, Yatabe Y, Mizuuchi H, Jangchul P, Kondo C, Shimoji M, Sato K, Suda K, Tomizawa K, Takemoto T, Hida T, Nishio K, Mitsudomi T. EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs Clin Cancer Res 2015 21(23):5305-13 PubMed ID: 26206867 DOI: 10.1158/1078-0432.CCR-15-1046

15188 Yoda A, Adelmant G, Tamburini J, Chapuy B, Shindoh N, Yoda Y, Weigert O, Kopp N, Wu SC, Kim SS, Liu H, Tivey T, Christie AL, Elpek KG, Card J, Gritsman K, Gotlib J, Deininger MW, Makishima H, Turley SJ, Javidi-Sharifi N, Maciejewski JP, Jaiswal S, Ebert BL, Rodig SJ, Tyner JW, Marto JA, Weinstock DM, Lane AA. Mutations in G protein β subunits promote transformation and kinase inhibitor resistance Nat Med 2015 21(1):71-5 PubMed ID: 25485910 DOI: 10.1038/nm.3751

4836 Tomita O, Iijima K, Ishibashi T, Osumi T, Kobayashi K, Okita H, Saito M, Mori T, Shimizu T, Kiyokawa N. Sensitivity of SNX2-ABL1 toward tyrosine kinase inhibitors distinct from that of BCR-ABL1. Leuk Res 2014 38(3):361-70 PubMed ID: 24367893 DOI: 10.1016/j.leukres.2013.11.017

4839 Nakaya Y, Shide K, Naito H, Niwa T, Horio T, Miyake J, Shimoda K. Effect of NS-018, a selective JAK2V617F inhibitor, in a murine model of myelofibrosis. Blood Cancer J 2014 4:e174 PubMed ID: 24413068 DOI: 10.1038/bcj.2013.73

4850 Yoshida R1, Kawahara M, Nagamune T. A novel platform for antibody library selection in mammalian cells based on a growth signalobody. Biotechnol Bioeng 2014 111(6):1170-9 PubMed ID: 24338724 DOI: 10.1002/bit.25173

4851 Yidan Ma, Teruyuki Nagamune, Masahiro Kawahara Split focal adhesion kinase for probing protein–protein interactions Biochemical Engineering Journal 2014 90:272-278 DOI: 10.1016/j.bej.2014.06.022

4857 Kawahara M, Hitomi A, Nagamune T. Antigen-responsive regulation of Cell motility and migration via the signalobodies based on c-Fms and c-Mpl. Biotechnol Prog 2014 30(2):411-7 PubMed ID: 24375974 DOI: 10.1002/btpr.1861

4858 Saka K, Kawahara M, Nagamune T. Quantitative control of intracellular signaling activity through chimeric receptors incorporating multiple identical tyrosine motifs. Biotechnol Bioeng 2014 111(5):948-55 PubMed ID: 24222636 DOI: 10.1002/bit.25151

4866 Kodama T, Tsukaguchi T, Satoh Y, Yoshida M, Watanabe Y, Kondoh O, Sakamoto H. Alectinib shows potent antitumor activity against RET-rearranged non-small cell lung cancer. Mol Cancer Ther 2014 13(12):2910-8 PubMed ID: 25349307 DOI: 10.1158/1535-7163.MCT-14-0274

12522 Kato A, Fujii E, Watanabe T, Takashima Y, Matsushita H, Furuhashi T, Morita A. Distribution of IL-31 and its receptor expressing cells in skin of atopic dermatitis J Dermatol Sci 2014 4(3):229-35 PubMed ID: 24667097 DOI: 10.1016/j.jdermsci.2014.02.009

18280 Oh B, Kim TY, Min HJ, Kim M, Kang MS, Huh JY, Kim Y, Lee DS. Synergistic killing effect of imatinib and simvastatin on imatinib-resistant chronic myelogenous leukemia cells Anticancer Drugs 2013 24(1):20-31 PubMed ID: 23075630 DOI: 10.1097/CAD.0b013e32835a0fbd

18602 Cox JH, Hussell S, Søndergaard H, Roepstorff K, Bui JV, Deer JR, Zhang J, Li ZG, Lamberth K, Kvist PH, Padkjær S, Haase C, Zahn S, Odegard VH. Antibody-mediated targeting of the Orai1 calcium channel inhibits T cell function PLoS One 2013 8(12):e82944 PubMed ID: 24376610 DOI: 10.1371/journal.pone.0082944

4838 Li SQ, Cheuk AT, Shern JF, Song YK, Hurd L, Liao H, Wei JS, Khan J. Targeting wild-type and mutationally activated FGFR4 in rhabdomyosarcoma with the inhibitor ponatinib (AP24534). PLoS One 2013 8(10):e76551 PubMed ID: 24124571 DOI: 10.1371/journal.pone.0076551

4841 Takagi M, Sato M, Piao J, Miyamoto S, Isoda T, Kitagawa M, Honda H, Mizutani S. ATM-dependent DNA damage-response pathway as a determinant in chronic myelogenous leukemia. DNA Repair (Amst) 2013 12(7):500-7 PubMed ID: 23694754 DOI: 10.1016/j.dnarep.2013.04.022

4845 Nakabayashi H, Kawahara M, Tanaka K, Nagamune T. Construction of antibody/insulin receptor chimera for growth induction of mammalian cells. Cytotechnology 2013 65(6):945-53 PubMed ID: 23615961 DOI: 10.1007/s10616-013-9571-5

4846 Saka K, Kawahara M, Nagamune T. Reconstitution of a cytokine receptor scaffold utilizing multiple different tyrosine motifs. Biotechnol Bioeng 2013 110(12):3197-204 PubMed ID: 23775041 DOI: 10.1002/bit.24973

4855 Tone Y, Kawahara M, Hayashi J, Nagamune T. Cell fate conversion by conditionally switching the signal-transducing domain of signalobodies. Biotechnol Bioeng 2013 110(12):3219-26 PubMed ID: 23794462 DOI: 10.1002/bit.24985

4861 Saka K, Kawahara M, Teng J, Otsu M, Nakauchi H, Nagamune T. Top-down motif engineering of a cytokine receptor for directing ex vivo expansion of hematopoietic stem cells. J Biotechnol 2013 168(4):659-65 PubMed ID: 24070902 DOI: 10.1016/j.jbiotec.2013.09.012

16424 Nakamura M, Uehara Y, Asada M, Suzuki M, Imamura T. Sulfated glycosaminoglycan-assisted receptor specificity of human fibroblast growth factor (FGF) 19 signaling in a mouse system is different from that in a human system J Biomol Screen 2013 18(3):321-30 PubMed ID: 23064887 DOI: 10.1177/1087057112463820

4837 Kaneda M1, Odaka T, Suetake H, Tahara D, Miyadai T. Teleost IL-6 promotes antibody production through STAT3 signaling via IL-6R and gp130. Dev Comp Immunol 2012 38(2):224-31 PubMed ID: 22469658 DOI: 10.1016/j.dci.2012.02.002

4854 Shindoh N, Yoda A, Yoda Y, Sullivan TJ, Weigert O, Lane AA, Kopp N, Bird L, Rodig SJ, Fox EA, Weinstock DM. Next-generation cDNA screening for oncogene and resistance phenotypes. PLoS One 2012 7(11):e49201 PubMed ID: 23145123 DOI: 10.1371/journal.pone.0049201

4880 Itonaga H, Tsushima H, Hata T, Matsuo E, Imanishi D, Imaizumi Y, Kawaguchi Y, Fukushima T, Doi Y, Mori S, Kamihira S, Tomonaga M, Miyazaki Y. Successful treatment of a chronic-phase T-315I-mutated chronic myelogenous leukemia patient with a combination of imatinib and interferon-alfa. Int J Hematol 2012 95(2):209-13 PubMed ID: 22262141 DOI: 10.1007/s12185-012-1005-1

7791 Nakamura M, Uehara Y, Asada M, Honda E, Nagai N, Kimata K, Suzuki M, Imamura T. Sulfated glycosaminoglycans are required for specific and sensitive fibroblast growth factor (FGF) 19 signaling via FGF receptor 4 and betaKlotho. J. Biol. Chem. 2011 286:26418-23 PubMed ID: 21653700 DOI: 10.1074/jbc.M111.251140

4844 Tsuruyama T, Hiratsuka T, Jin G, Imai Y, Takeuchi H, Maruyama Y, Kanaya K, Ozeki M, Takakuwa T, Haga H, Tamaki K, Nakamura T. Murine leukemia retrovirus integration induces the formation of transcription factor complexes on palindromic sequences in the signal transducer and activator of transcription factor 5a gene during the development of pre-B lymphomagenesis. Am J Pathol 2011 178(3):1374-86 PubMed ID: 21356387 DOI: 10.1016/j.ajpath.2010.12.012

15721 Shen M, Siu S, Byrd S, Edelmann KH, Patel N, Ketchem RR, Mehlin C, Arnett HA, Hasegawa H. Diverse functions of reactive cysteines facilitate unique biosynthetic processes of aggregate-prone interleukin-31 Exp Cell Res 2011 317(7):976-93 PubMed ID: 21182835 DOI: 10.1016/j.yexcr.2010.12.012

4888 Ikezoe T, Takeuchi T, Yang J, Adachi Y, Nishioka C, Furihata M, Koeffler HP, Yokoyama A. Analysis of Aurora B kinase in non-Hodgkin lymphoma. Lab Invest 2009 89(12):1364-73 PubMed ID: 19823168 DOI: 10.1038/labinvest.2009.106

18169 Yamane N, Tanaka Y, Ohyabu N, Yamane S, Maekawa K, Ishizaki J, Suzuki R, Itoh T, Takemoto H. Characterization of novel non-peptide thrombopoietin mimetics, their species specificity and the activation mechanism of the thrombopoietin receptor Eur J Pharmacol 2008 586(1-3):44-51 PubMed ID: 18377892 DOI: 10.1016/j.ejphar.2008.02.060

4856 Asada M, Honda E, Imamura T. Biologically active fibroblast growth factor 1 tagged with various epitopes. BMC Res Notes 2008 1:42 PubMed ID: 18710495 DOI: 10.1186/1756-0500-1-42

4876 Takada A, Yoshida S, Kajikawa M, Miyatake Y, Tomaru U, Sakai M, Chiba H, Maenaka K, Kohda D, Fugo K, Kasahara M. Two novel NKG2D ligands of the mouse H60 family with differential expression patterns and binding affinities to NKG2D. J Immunol 2008 180(3):1678-85 PubMed ID: 18209064 DOI: 10.4049/jimmunol.180.3.1678

14416 Yamane N, Takahashi K, Tanaka Y, Kato K, Takayama M, Ohyabu N, Shiota T, Takenaka H, Yoshida Y, Hara S, Murashi T, Nakamura E, Nishitani Y, Ishizaki J, Yamane S, Nagata K, Koizumi K, Yutsudo T, Suzuki R, Itoh T, Takemoto H. Discovery of novel non-peptide thrombopoietin mimetic compounds that induce megakaryocytopoiesis Biosci Rep . 2008 Oct;28(5):275-85 2008 28(5):275-85 PubMed ID: 18620546 DOI: 10.1042/BSR20080086

16421 Motomura K, Hagiwara A, Komi-Kuramochi A, Hanyu Y, Honda E, Suzuki M, Kimura M, Oki J, Asada M, Sakaguchi N, Nakayama F, Akashi M, Imamura T. An FGF1:FGF2 chimeric growth factor exhibits universal FGF receptor specificity, enhanced stability and augmented activity useful for epithelial proliferation and radioprotection Biochim Biophys Acta 2008 1780(12):1432-40 PubMed ID: 18760333 DOI: 10.1016/j.bbagen.2008.08.001

2882 Maeda T, Yagasaki F, Ishikawa M, Takahashi N, Bessho M. Transforming property of TEL-FGFR3 mediated through PI3-K in a T-cell lymphoma that subsequently progressed to AML. Blood 2005 105(5):2115-23 PubMed ID: 15514005 DOI: 10.1182/blood-2003-12-4290

4879 Nawata R, Yujiri T, Nakamura Y, Ariyoshi K, Takahashi T, Sato Y, Oka Y, Tanizawa Y. MEK kinase 1 mediates the antiapoptotic effect of the Bcr-Abl oncogene through NF-kappaB activation. Oncogene 2003 22(49):7774-80 PubMed ID: 14586403 DOI: 10.1038/sj.onc.1206901

4884 Kiyoi H, Ohno R, Ueda R, Saito H, Naoe T. Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain Oncogene 2002 21(16):2555-63 PubMed ID: 11971190 DOI: 10.1038/sj.onc.1205332

2559 Shimizu A, Tada K, Shukunami C, Hiraki Y, Kurokawa T, Magane N, Kurokawa-Seo M A novel alternatively spliced fibroblast growth factor receptor 3 isoform lacking the acid box domain is expressed during chondrogenic differentiation of ATDC5 cells. J Biol Chem 2001 276:11031-40 PubMed ID: 11134040 DOI: 10.1074/jbc.M003535200

4871 Feng R, Kabayama A, Uchida K, Hoshino H, Miwa M. Cell-free entry of human T-cell leukemia virus type 1 to mouse cells. Jpn J Cancer Res 2001 92(4):410-6 PubMed ID: 11346463 DOI: 10.1111/j.1349-7006.2001.tb01110.x

16915 Sun W, Hattori N, Mutai H, Toyoshima Y, Kimura H, Tanaka S, Shiota K. PAL31, a nuclear protein required for progression to the S phase Biochem Biophys Res Commun 2001 280(4):1048-54 PubMed ID: 11162633 DOI: 10.1006/bbrc.2000.4244

4832 Kawasaki K1, Akashi S, Shimazu R, Yoshida T, Miyake K, Nishijima M. Mouse toll-like receptor 4.MD-2 complex mediates lipopolysaccharide-mimetic signal transduction by Taxol. J Biol Chem 2000 275(4):2251-4 PubMed ID: 10644670 DOI: 10.1074/jbc.275.4.2251

4840 Tsunekawa B, Wada M, Ikeda M, Banba S, Kamachi H, Tanaka E, Honjo M. The binding between the stem regions of human growth hormone (GH) receptor compensates for the weaker site 1 binding of 20-kDa human GH (hGH) than that of 22-kDa hGH. J Biol Chem 2000 275(21):15652-6 PubMed ID: 10748003 DOI: 10.1074/jbc.M001236200

4853 Odajima J, Matsumura I, Sonoyama J, Daino H, Kawasaki A, Tanaka H, Inohara N, Kitamura T, Downward J, Nakajima K, Hirano T, Kanakura Y. Full oncogenic activities of v-Src are mediated by multiple signaling pathways. Ras as an essential mediator for cell survival. J Biol Chem 2000 275(31):24096-105 PubMed ID: 10918073 DOI: 10.1074/jbc.m001606200

3112 Yoneda A, Asada M, Oda Y, Suzuki M, Imamura T. Engineering of an FGF-proteoglycan fusion protein with heparin-independent, mitogenic activity. Nat Biotechnol 2000 18(6):641-4 PubMed ID: 10835602 DOI: 10.1038/76487

4831 Kume A1, Ito K, Ueda Y, Hasegawa M, Urabe M, Mano H, Ozawa K. A G-CSF receptor-gyrase B fusion gene: A new type of molecular switch for expansion of genetically modified hematopoietic cells. Biochem Biophys Res Commun 1999 260(1):9-12 PubMed ID: 10381335 DOI: 10.1006/bbrc.1999.0859

4833 Matsuda KM, Kume A, Ueda Y, Urabe M, Hasegawa M, Ozawa K. Development of a modified selective amplifier gene for hematopoietic stem cell gene therapy Gene Ther 1999 6(6):1038-44 PubMed ID: 10455406 DOI: 10.1038/sj.gt.3300906

4834 Xu R, Kume A, Matsuda KM, Ueda Y, Kodaira H, Ogasawara Y, Urabe M, Kato I, Hasegawa M, Ozawa K. A selective amplifier gene for tamoxifen-inducible expansion of hematopoietic cells. J Gene Med 1999 1(4):236-44 PubMed ID: 10738556 DOI: 10.1002/(SICI)1521-2254(199907/08)1:4<236::AID-JGM42>3.0.CO;2-2

4848 Yoneda A, Asada M, Suzuki M, Imamura T. Introduction of an N-glycosylation cassette into proteins at random sites: expression of neoglycosylated FGF. Biotechniques 1999 27(3):576-8 PubMed ID: 10489617 DOI: 10.2144/99273rr05

2439 Tsunekawa B, Wada M, Ikeda M, Uchida H, Naito N, Honjo M. The 20-kilodalton (kDa) human growth hormone (hGH) differs from the 22-kDa hGH in the effect on the human prolactin receptor Endocrinology 1999 140(9):3909-18 PubMed ID: 10465259 DOI: 10.1210/endo.140.9.6959

2271 Wada M, Uchida H, Ikeda M, Tsunekawa B, Naito N, Banba S, Tanaka E, Hashimoto Y, Honjo M. The 20-kilodalton (kDa) human growth hormone (hGH) differs from the 22-kDa hGH in the complex formation with cell surface hGH receptor and hGH-binding protein circulating in human plasma. Mol Endocrinol 1998 2(1):146-56 PubMed ID: 9440818 DOI: 10.1210/mend.12.1.0054

18069 Chin H, Wakao H, Miyajima A, Kamiyama R, Miyasaka N, Miura O. Erythropoietin induces tyrosine phosphorylation of the interleukin-3 receptor beta subunit (betaIL3) and recruitment of Stat5 to possible Stat5-docking sites in betaIL3 Blood 1997 89(12):4327-36 PubMed ID: 9192755

4830 Sasaki M, Sasaki T, Enami J. Prolactin-dependent growth and gamma-casein gene expression in Ba/F3 cells transfected with a long form of mouse mammary prolactin receptor. Endocr J 1996 43(1):45-52 PubMed ID: 8732451 DOI: 10.1507/endocrj.43.45

4883 Palaga T, Kataoka T, Woo JT, Nagai K. Suppression of apoptotic cell death of IL-3-dependent cell lines by ER/SR Ca2+-ATPase inhibitors upon IL-3 deprivation. Exp Cell Res 1996 228(1):92-7 PubMed ID: 8892975 DOI: 10.1006/excr.1996.0303

4835 Miyake K, Yamashita Y, Ogata M, Sudo T, Kimoto M. RP105, a novel B cell surface molecule implicated in B cell activation, is a member of the leucine-rich repeat protein family. J Immunol 1995 154(7):3333-40 PubMed ID: 7897216